Interní Med. 2002; 4(1): 6-9

Hepatorenální syndrom

doc. MUDr. Jan Lata CSc, MUDr. Michal Šenkyřík
III. interní klinika gastroenterologická, FN Brno-Bohunice

Keywords: hepatorenal syndrome, liver cirrhosis, portal hypertension.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lata J, Šenkyřík M. Hepatorenální syndrom. Interní Med. 2002;4(1):6-9.

V článku jsou uvedeny základní informace o jednom z důsledků cirhózy a portální hypertenze - hepatorenálním syndromu. Je uvedena patofyziologie tohoto stavu, klinický obraz, diagnostika a jsou diskutovány možnosti léčby (včetně efektivity podání terlipresinu s albuminem a zavedení transjugulární portosystémové spojky) a především nutnost prevence. Na závěr je uvedeno přehledné schéma doporučeného postupu.

Hepatorenal syndrome

In the paper are discussed pathophysiology, symptoms and diagnosis of one of the consequences of portal hypertension - hepatorenal syndrome. The possibilities of treatment are point out, especially combination of terlipressin with albumin and transjugular intrahepatic portosystemic shunt. The recommended procedure is presented in the end of the paper.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arroyo V, Ginés P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-173. Go to original source... Go to PubMed...
    2. Bataller R, Ginés P, Arroyo V et al. Hepatorenal syndrome. Semin Liver Dis 1997; 17: 233-247. Go to original source... Go to PubMed...
    3. Ganne-Carrie A, Hadengue A, Mathurin P, et al. Hepatorenal syndrome. Longterm treatment with terlipressin as a bridge to liver transplantaation. Dig Dis Sci 1996; 41, 6: 1054/1056. Go to original source... Go to PubMed...
    4. Guevara M, Ginnés P, Rodés J, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-422. Go to original source... Go to PubMed...
    5. Guevara M, Ginés P, Rodés J, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41. Go to original source... Go to PubMed...
    6. Hůlek P, Krajina A editors. Current practice of TIPS. OŠ Publishing, 2001.
    7. Jalan R, Forrest EH, Hayes PC, et al. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997; 40: 664-670. Go to original source... Go to PubMed...
    8. Jarčuška P, Hildebrand T, Zakuciová M. Reverzibilita hepatorenálného syndrómu dlhotrvajúcím podáváním terlipressinu (Remestyp) v kombinácii s plazmaexpanziou popis 2 pripadov Chirurgický zpravodaj 1999; 2: 39-44.
    9. Lafayette RA, Paare G, Schmid CH, et al. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997; 48, 3: 159-164. Go to PubMed...
    10. Moore K. The hepatorenal syndrome. Clin Sci 1997; 92: 433-443. Go to original source... Go to PubMed...
    11. Moreau R, Durand F, Poynard T, et al. Improved renal function is associated with increased survival in patients with cirrhosis and type 1 hepatorenal syndrome (HRS) treated with terlipressin. A retrospective multicenter study. Hepatology, 2001; 34, 4, pt 2: 541 A. Go to original source...
    12. Quiroga J, Sangro B, Nunez M, et al. Transjugular intrahepatic portal-systemic shunt in the management of refractory ascites: Effect on clinical, renal, humoral and hemodynamic parameters. Hepatology 1995; 21: 986-994. Go to original source... Go to PubMed...
    13. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.